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Pegylated-Interferon alpha (Peginfa) treatment of patients
with polycythemia vera or essential thrombocythemia has
resulted in long-term clinical response, decrease JAK2V617F
allelic burden and restoration of polyclonal hematopoiesis.
Characterizing the peripheral blood lymphocytes (PB)
repertoire allows for monitoring the effect of immune-
based therapies such as Peginfa. Here we analyzed the
phenotype and frequency of PB lymphocytes from Peginfa
treated patients and compared them to patients treated
with cytoreductive drugs.
Samples collected pre and at various time during treat-
ment were analyzed using a multicolor flow cytometry
panel containing antibodies to CD3, CD4, CD8, CD25,
CD56, CD38, CD39, CD45RO, CD197, HLA-DR, PD-1,
OX40, 4-1BB, CTLA-4, Foxp3, Helios and Ki-67.
We found that Peginfa increased the frequency of PB
Foxp3+ CD4+ regulatory T cells (Treg) from 6.43% to
9.62% (p=0.0033). Highly suppressive Treg, characterized
by co-expression of CD39 and HLA-DR were also
increased in PB from Peginfa treated patients (18.92% to
22.92, p=0.0401). We also found an augmentation of
cycling CD8+ T cells (4.6% to 7.45% (p=0.0010)) and NK
from 8.54% to 17.49 % (p=0.0156) cells as measured by
expression marker Ki-67.
Our results also show that Peginfa increased the fre-
quency of PD-1+ CD4+ helper cells (p=0.0028), PD-1+
CD4+ Foxp3+ Treg cells (p=0.0129) and PD1+ CD8+
T cells (p=0.0391). We did not observe any changes in
these lymphocyte populations in the PB of hydroxyurea
treated patients.
Overall these results indicate that there is a strong sti-
mulation of the immune response as measured in the PB
that may contribute to eradication of JAK2v617F clones.
These results will be correlated with JAK2v617F allelic bur-
den and for female patients, with recovery of a polyclonal
hematopoiesis as measured by X chromosome allelic
usage. More studies need to be performed on bone mar-
row lymphocytes to determine the composition and func-
tion of T cells in the vicinity of JAK2V617F positive clones.
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